Abstract
We have previously shown significant hemostatic derangements associated with IVH and have questioned the use of indomethacin [I] , a potent platelet anti-aggregating agent in infants vulnerable to IVH. During a prospective study of [I] prophylaxis for patent ductus arteriosus (PDA), we assessed the impact of [I] upon the incidence of IVH.
Sixty one inborn infants were randomized by birth weight (Group A: <900 gm; Group B: 900-1300 gm) to receive either placebo [P] or [I] . The first dose (0.2 mg/kg), given within 12 hours after birth, was followed by two q 12 hourly doses (0.1 mg/kg). Cranial ultrasonography was performed prior to dose # 1, daily for 3 days and at 1 week. Abnormal scans were repeated weekly. The most severe grade of IVH (Papile criteria) sustained by each infant is shown below:
In Group A, 2 of 10 (20%) of infants who received I developed IVH (Grades II-IV) in contrast to 8 of 10 (80%) of infants given [P], p < 0.025. In Group B, there was no significant difference in IVH between [I] and [P] These preliminary data suggest that prophylactic [I] may diminish the incidence of IVH in infants < 900 grams, perhaps by preventing clinically significant PDA or by altering prostaglandin-related central nervous system vascular phenomena.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Setzer, E., Morse, B., Goldberg, R. et al. PROPHYLACTIC INDOMETHACIN AND INTRAVENTRICULAR HEMORRHAGE (IVH) IN THE PREMATURE. Pediatr Res 18 (Suppl 4), 345 (1984). https://doi.org/10.1203/00006450-198404001-01515
Issue Date:
DOI: https://doi.org/10.1203/00006450-198404001-01515
This article is cited by
-
Effects of prolonged versus acute indomethacin therapy in very low birth-weight infants with patent ductus arteriosus
European Journal of Pediatrics (1988)